Namibia - English - Namibia Medicines Regulatory Council

glaxosmithkline south africa (pty) ltd - polymixin b sulphate, neomycin sulphate , hydrocortisone - ear drops - each ml contains polymixin b sulphate 10,000 iu, neomycin sulphate 3,400 iu, hydrocortisone 10mg

Canada - English - Health Canada

sandoz canada incorporated - cyclosporine - capsule - 25mg - cyclosporine 25mg - immunosuppressive agents

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - cyclosporin -

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 10 mg - capsule, soft - excipient ingredients: corn glycerides; ethanol; propylene glycol; dl-alpha-tocopherol; peg-40 hydrogenated castor oil; glycerol; gelatin; titanium dioxide; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see precautions). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with the quality of life. for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 100 mg - capsule, soft - excipient ingredients: ethanol; iron oxide black; propylene glycol; gelatin; glycerol; peg-40 hydrogenated castor oil; titanium dioxide; corn glycerides; dl-alpha-tocopherol; hypromellose; purified water; isopropyl alcohol; cochineal; aluminium chloride; sodium hydroxide - as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cystostatic drugs have failed, or are not tolerated, or are considered inapropriate, and when renal function is unimpaired (see warnings). for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. additional indications from 11 june 1997: for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 50 mg/ml - injection, concentrated - excipient ingredients: peg-35 castor oil; ethanol - this product is accepted for registration as 'currently supplied' at the time of commencement of the act. new indications were approved as specified in the letter of 16 june 1992 from dr l. hunt. indications: as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. extended indications as at 15 october 1993: for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired . indications as at 11 february 1994 from dr j mcginness: 1. as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. 2. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasi

Israel - English - Ministry of Health

novartis israel ltd - ciclosporin - capsules - ciclosporin 100 mg - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

Israel - English - Ministry of Health

novartis israel ltd - ciclosporin - capsules - ciclosporin 25 mg - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

Israel - English - Ministry of Health

novartis israel ltd - ciclosporin - capsules - ciclosporin 50 mg - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

United States - English - NLM (National Library of Medicine)

abbvie inc. - cyclosporine (unii: 83hn0gtj6d) (cyclosporine - unii:83hn0gtj6d) - cyclosporine 100 mg in 1 ml - gengraf® oral solution (cyclosporine oral solution, usp [modified ]) is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. cyclosporine (modified ) has been used in combination with azathioprine and corticosteroids. gengraf® oral solution (cyclosporine oral solution, usp [modified ]) is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. gengraf® can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. gengraf® oral solution (cyclosporine oral solution, usp [modified ]) is indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., puva, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated, or can